Hemex Gazelle

Hemex Gazelle provides affordable and accurate Beta Thalassemia screening to populations which located at sites where it is needed most. Hemex innovates by designing Gazelle, a product that listens the need of healthcare providers including those located in remote and challenging settings. Initial test includes Beta Thalassemia detection as one of the hemoglobin disorders (hemoglobinopathy).

Gazelle® for Point of Care Testing (POCT) identifies Beta Thalassemia Rapidly, easily and inexpensively.

More than 6% of the world’s population are at risk of inheriting hemoglobin disorder, including Beta Thalassemia. In Indonesia, there are approximately 3% of Thalassemia patients and the prevalence increases every year. Thalassemia is a hereditary disease, early diagnosis can prevent tens of thousands of child deaths each year.

Gazelle Hb Variant is a miniaturized version of the gold standard testing known as electrophoresis. Performing the test does not require an expert and only requires minimal training. Results are displayed in 8 minutes, including the quantification of each hemoglobin type (HbA, HbF and Hb S, Hb A2/C/E). The results can be stored locally or transferred to the cloud to allow patient and disease tracking.